Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), according to a subgroup analysis of the PHOTON trial presented at the recent ...

Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular ...

Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by ...

In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses a preliminary study of combination gene therapy targeting neovascular age-related ...

A study shows the ways in which brolucizumab can provide superior AMD therapy to some patients compared with aflibercept.

The U.S. FDA’s decision to grant breakthrough device designation for Bivacor Inc.’s titanium total artificial heart (TAH) ...

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China. Phase 2 data suggest ...

Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial. The current wet ...

Following is a transcript of his remarks: I had the privilege to present data of a study that we did to compare faricimab studies to the 8-mg aflibercept studies. It's difficult to compare trials ...